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Nathan C Lo and colleagues (October, 
2015)1 conclude that community-
wide treatment programmes can be 
a highly cost-eﬀ ective way to cont rol 
morbidity of schistosomiasis and soil-
transmitted helminthiasis, even in 
communities with low disease burden. 
This work is a timely contribution 
to an important issue; however, 
methodological shortcomings aﬀ ect 
the conclusions.
Within the model, the health 
burden of schistosomiasis over time 
was estimated by simply assigning a 
disability-adjusted life-year (DALY) 
weight to the prevalence of infection, 
as in a cross-sectional Global Burden 
of Disease study. This estimation 
corresponded to more than 92% of 
the projected disease burden averted 
within the study (measured in DALY).
However, this approach will probably 
significantly overestimate the effect 
and hence the cost-effectiveness 
of community-wide treatment 
because it does not differentiate 
between prevention of heavy and 
light infections (the former being 
associated with morbidity)—this could 
be avoided by estimating burden on 
the basis of intensity of infection.2 
The effect of mass drug admin-
istration on transmission also depends 
on the relation between worm burden 
and egg production (which declines 
as burden increases). This relation has 
been shown to vary between species3 
and aﬀ ects assumptions with respect 
to the underlying burden and the 
eﬀ ectiveness of control. By assuming 
that the relation is the same across 
species, Lo and colleagues run the 
risk of overestimating the effect of 
community-wide treatment for some 
species. 
Community-wide treatment can 
be a powerful intervention against 
soil-transmitted helminthiasis and 
schistosomiasis, but the eﬀ ect is highly 
dependent on the epidemiological 
setting.4,5 For example, although 
community-wide treatment is probably 
essential to fully control hookworm’s 
morbidity, it might not be needed in 
regions that are dominated by Ascaris 
lumbricoides or Trichuris trichiura.4,5 
Community-wide treatment to control 
morbidity could cost-effective in 
some settings, but the investigators 
might have overestimated its cost-
eﬀ ectiveness, particularly in areas with 
a low disease burden. 
Because of obvious programmatic 
and financial constraints, the 
implementation of community-wide 
treatment will not be possible in 
every location in which these diseases 
are endemic. A large change in policy 
will necessitate analysis of a range 
of approaches and epidemiological 
settings. The benefit in many areas 
will not lie in morbidity control but 
in the capacity to accelerate progress 
to elimination, thereby reducing 
the programme’s duration (which is 
potentially cost saving).5–7 Ultimately, 
whether community-wide treatment 
is appropriate or not will depend 
on the epidemiological setting 
and whether the goal is to control 
morbidity or break transmission.
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